Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
COVID-19 is a disease caused by a novel coronavirus with no specific, standard treatment. We investigated the clinical data of COVID-19 patients admitted to King Fahad Specialist Hospital (KFSH) in Buraydah by comparing the patients who were treated early with favipiravir (within 3 days of admission...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Advances in Virology |
| Online Access: | http://dx.doi.org/10.1155/2022/9240941 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565701635735552 |
|---|---|
| author | Abdulrahman Tawfik Abdulrahman Alzahrani Sami Alharbi Jamal Almitairi Arwa Alzahrani Mohammed Ali Alshehri Mohammed S. Aldughaim Hani Alothaid |
| author_facet | Abdulrahman Tawfik Abdulrahman Alzahrani Sami Alharbi Jamal Almitairi Arwa Alzahrani Mohammed Ali Alshehri Mohammed S. Aldughaim Hani Alothaid |
| author_sort | Abdulrahman Tawfik |
| collection | DOAJ |
| description | COVID-19 is a disease caused by a novel coronavirus with no specific, standard treatment. We investigated the clinical data of COVID-19 patients admitted to King Fahad Specialist Hospital (KFSH) in Buraydah by comparing the patients who were treated early with favipiravir (within 3 days of admission) to patients who were treated after three days of admission or not treated. 165 patients were confirmed with PCR tests and admitted to KFSH for treatment. Comorbidities contributed significantly to increasing the length of stay in hospital at 11.4 ± 0.8 days compared to patients with no comorbidities at 8.6 ± 0.9 days (p=0.041). A total of 103 patients were treated with favipiravir, and we found that early treatment with favipiravir (within 3 days) reduced the length of stay in hospital significantly (8.8 ± 1.4 days) compared to patients who were treated after 3 days (13.3 ± 4.6 days) (p=0.0015). Moreover, patients with comorbidities in both early and late treatment groups had significantly higher average lengths of stay in hospital (11.2 ± 0.9 days) compared to patients with no comorbidities (7.9 ± 0.7 days) (p=0.017). Interestingly, patients treated early with favipiravir (with comorbidities and without) stayed fewer days in hospital compared to those with late treatment (p=0.021; a difference of 4.5 ± 1.9 days; and p=0.018; a difference of 4.2 ± 1.7 days, respectively). In conclusion, our analysis indicates that early treatment with favipiravir can reduce the length of stay in hospital and improve clinical manifestations of COVID-19 patients. |
| format | Article |
| id | doaj-art-2622d22dbdb340cb9dbd22670a0220f8 |
| institution | Kabale University |
| issn | 1687-8647 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Virology |
| spelling | doaj-art-2622d22dbdb340cb9dbd22670a0220f82025-02-03T01:06:47ZengWileyAdvances in Virology1687-86472022-01-01202210.1155/2022/9240941Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 PatientsAbdulrahman Tawfik0Abdulrahman Alzahrani1Sami Alharbi2Jamal Almitairi3Arwa Alzahrani4Mohammed Ali Alshehri5Mohammed S. Aldughaim6Hani Alothaid7Medical Cluster of Infection Prevention and ControlDepartment of Applied Medical SciencesDepartment of Internal MedicineDepartment of Clinical Service LineCollege of MedicineFaculty of Applied Medical SciencesResearch CenterFaculty of Applied Medical SciencesCOVID-19 is a disease caused by a novel coronavirus with no specific, standard treatment. We investigated the clinical data of COVID-19 patients admitted to King Fahad Specialist Hospital (KFSH) in Buraydah by comparing the patients who were treated early with favipiravir (within 3 days of admission) to patients who were treated after three days of admission or not treated. 165 patients were confirmed with PCR tests and admitted to KFSH for treatment. Comorbidities contributed significantly to increasing the length of stay in hospital at 11.4 ± 0.8 days compared to patients with no comorbidities at 8.6 ± 0.9 days (p=0.041). A total of 103 patients were treated with favipiravir, and we found that early treatment with favipiravir (within 3 days) reduced the length of stay in hospital significantly (8.8 ± 1.4 days) compared to patients who were treated after 3 days (13.3 ± 4.6 days) (p=0.0015). Moreover, patients with comorbidities in both early and late treatment groups had significantly higher average lengths of stay in hospital (11.2 ± 0.9 days) compared to patients with no comorbidities (7.9 ± 0.7 days) (p=0.017). Interestingly, patients treated early with favipiravir (with comorbidities and without) stayed fewer days in hospital compared to those with late treatment (p=0.021; a difference of 4.5 ± 1.9 days; and p=0.018; a difference of 4.2 ± 1.7 days, respectively). In conclusion, our analysis indicates that early treatment with favipiravir can reduce the length of stay in hospital and improve clinical manifestations of COVID-19 patients.http://dx.doi.org/10.1155/2022/9240941 |
| spellingShingle | Abdulrahman Tawfik Abdulrahman Alzahrani Sami Alharbi Jamal Almitairi Arwa Alzahrani Mohammed Ali Alshehri Mohammed S. Aldughaim Hani Alothaid Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients Advances in Virology |
| title | Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients |
| title_full | Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients |
| title_fullStr | Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients |
| title_full_unstemmed | Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients |
| title_short | Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients |
| title_sort | effectiveness of early favipiravir therapy in hospitalised covid 19 patients |
| url | http://dx.doi.org/10.1155/2022/9240941 |
| work_keys_str_mv | AT abdulrahmantawfik effectivenessofearlyfavipiravirtherapyinhospitalisedcovid19patients AT abdulrahmanalzahrani effectivenessofearlyfavipiravirtherapyinhospitalisedcovid19patients AT samialharbi effectivenessofearlyfavipiravirtherapyinhospitalisedcovid19patients AT jamalalmitairi effectivenessofearlyfavipiravirtherapyinhospitalisedcovid19patients AT arwaalzahrani effectivenessofearlyfavipiravirtherapyinhospitalisedcovid19patients AT mohammedalialshehri effectivenessofearlyfavipiravirtherapyinhospitalisedcovid19patients AT mohammedsaldughaim effectivenessofearlyfavipiravirtherapyinhospitalisedcovid19patients AT hanialothaid effectivenessofearlyfavipiravirtherapyinhospitalisedcovid19patients |